Latest News

12July 2017

European Stroke Organization Conference

Two new randomized clinical trials of percutaneous patent foramen ovale (PFO) device closure have shown superiority of device closure over medical management for the prevention of recurrent stroke.

19February 2017

Call To Revise AHA/ASA Stroke Guidelines

The AHA/ASA Clinical Practice Guidelines on stroke prevention published in 2014 changed the previous percutaneous PFO closure indications (2006, 2011) from class II to class III. This change occurred despite the 2012 publication of [...]

19February 2017


The RESPECT Trial (Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment) is a multicenter (62 USA, 7 Canada) prospective 1:1 randomization superiority trial of patients 18-60 years [...]

19February 2017

No Change for ICD 10 Septal Defect Coding

ICD 9 diagnostic coding (745.5) and CPT therapeutic coding (93580) for defects of the atrial septum have not differentiated between defects of the fossa ovalis including ostium secundum defects (ASD II and PFO), fenestrations, [...]

21December 2016

FDA Approves PFO Closure

December 21, 2016 AMPLATZER™PFO Occluder PMA Approval The Amplatzer™ PFO Occluder device received Pre-Market Approval (PMA) by the US Food and Drug Administration on October 28, 2016 for the prevention of recurrent paradoxical embolic [...]